LIGAND PHARMACEUTICALS INCORPORATED
Assets & Liabilities
| Period | Total Liabilities | Total Assets | Cash on Hand |
|---|---|---|---|
| Mar 2017 | $230.9M | $629.7M | $10.6M |
| Jun 2017 | $230.6M | $640.0M | $60.2M |
| Sep 2017 | $237.6M | $662.3M | $32.7M |
| Dec 2017 | $252.4M | $671.0M | $20.6M |
| Mar 2018 | $257.5M | $754.7M | $51.0M |
| Jun 2018 | $1.24B | $1.86B | $151.5M |
| Sep 2018 | $1.41B | $2.11B | $115.6M |
| Dec 2018 | $699.9M | $1.26B | $117.2M |
| Mar 2019 | $834.0M | $1.91B | $105.1M |
| Jun 2019 | $760.4M | $1.80B | $273.0M |
| Sep 2019 | $696.9M | $1.55B | $225.3M |
| Dec 2019 | $727.7M | $1.49B | $71.5M |
| Mar 2020 | $524.0M | $1.19B | $117.5M |
| Jun 2020 | $547.9M | $1.24B | $115.2M |
| Sep 2020 | $549.6M | $1.25B | $456.9M |
| Dec 2020 | $652.8M | $1.36B | $47.6M |
| Mar 2021 | $549.3M | $1.30B | $31.9M |
| Jun 2021 | $469.8M | $1.26B | $21.9M |
| Sep 2021 | $461.6M | $1.27B | $23.4M |
| Dec 2021 | $476.4M | $1.30B | $19.5M |
| Mar 2022 | $312.0M | $1.11B | $15.0M |
| Jun 2022 | $273.9M | $1.08B | $5.3M |
| Sep 2022 | $234.3M | $1.05B | $4.1M |
| Dec 2022 | $165.2M | $762.7M | $45.0M |
| Mar 2023 | $164.8M | $811.1M | $88.7M |
| Jun 2023 | $93.2M | $758.1M | $28.4M |
| Sep 2023 | $101.3M | $769.2M | $19.3M |
| Dec 2023 | $86.3M | $787.2M | $23.0M |
| Mar 2024 | $107.3M | $913.9M | $50.1M |
| Jun 2024 | $91.2M | $866.4M | $18.1M |
| Sep 2024 | $113.7M | $954.9M | $63.6M |
| Dec 2024 | $111.3M | $941.8M | $72.3M |
| Mar 2025 | $109.9M | $905.4M | $48.0M |
| Jun 2025 | $120.1M | $948.6M | $67.7M |
| Sep 2025 | $526.6M | $1.48B | $139.4M |
| Dec 2025 | $543.4M | $1.56B | $174.9M |
| Mar 2026 | $534.8M | $1.53B | $115.1M |
| Jun 2026 | $1.22B | $2.19B | $1.01B |